October 2026 hepatology news includes FDA approval of bepirovirsen for hepatitis B, new ACLF criteria, ACG cirrhosis guidance, and MASH trial data.
|Videos|November 24, 2015
Q&A With David Reich From Hahnemann University Hospital: ELAD System Shows Promise For Artificial Liver Function
Author(s)Adam Hochron
In the past patients with alcoholic liver disease may not have been considered viable options for liver transplants. A recent study looked at whether an artificial device could help these patients return to a normal quality of life.
Advertisement
In the past patients with alcoholic liver disease may not have been considered viable options for liver transplants. A recent study looked at whether an artificial device could help these patients return to a normal quality of life.
David J. Reich, MD, from Hahnemann University Hospital discussed the results of the study which were presented at the annual Liver Meeting in San Francisco.
Advertisement
Related to this article
HCPLive previews GOLD 2026 in Philadelphia, November 5-6, with sessions on the 2027 GOLD Report, mucus plugging, and exacerbations, plus expert interviews.
October 2026 allergy news: FDA approvals for berotralstat pellets and remibrutinib, RAPIDe-3 data in HAE, alpha-gal syndrome, and Viaskin Peanut Patch.
Skin clearance and route of administration drove treatment choices among 202 patients with psoriasis in the ENCOMPASS-PP discrete choice experiment.
Alexa Kimball, MD, MPH, reviews tulisokibart safety in hidradenitis suppurativa, its potential in patients with IBD, and what phase 3 trials must answer.
In 20 patients with PAH, lower baseline RVEF was linked to greater RV functional recovery and PVR reduction after 24 weeks of sotatercept, per a CHEST 2026 abstract.
In this segment of her interview, Kimball discusses phase 2b tulisokibart data in hidradenitis suppurativa and the rationale for targeting TL1A.
Oral prifemilast, a PDE4B-selective inhibitor, led to PASI 75 attainment in up to 57.4% of those with psoriasis at week 16 vs 10.8% with placebo.
Advertisement
Advertisement
Trending on HCPLive
1
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
2
Q&A: Tulisokibart Results and TL1A Inhibition in HS, With Alexa Kimball, MD, MPH
3
Risankizumab Shows Higher 3-Year Drug Survival in Psoriasis With PsA
4
Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab
5